More and more companies are joining forces with software developers to create innovative products. But many are learning the hard way that making next-generation digital therapeutics isn’t as easy as signing a partnership agreement.
Maya Desai
Advertisement
Articles by Maya Desai
While COVID-19 has shifted some of the rules, research reveals that practice changes were already afoot for market newcomers.
While COVID-19 has shifted the rules of the healthcare industry, research shows there was already progress on changes being made for how pharma companies are launching products.
Advertisement
Latest Updated Articles
- New Standards for First-to-Launch Players
Published: September 14th 2020 | Updated:
- Research Reveals New Launch Standards for First-to-Launch Pharma and Biotech Companies in the U.S.
Published: June 26th 2020 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Libtayo for Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma
2
The Situation We Faced: The Development and Commercialization of MariTide
3
Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform
4
Novo Nordisk Enters $4.7 Billion Definitive Agreement with Akero Therapeutics
5
